Analystreport

LogicBio Therapeutics Inc (NASDAQ: LOGC) had its "buy" rating re-affirmed by analysts at William Blair.

ContextLogic Inc. - Class A  (LOGC) 
Last contextlogic inc. - class a earnings: 8/13 08:00 am Check Earnings Report